Screener
BioMarin Pharmaceuticals BMRN Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001048477-26-000016
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Depreciation and amortization | 114,049 | 40,632 |
| Non-cash interest expense | 27,912 | 1,320 |
| Stock-based compensation | 119,152 | 85,231 |
| Impairment of assets | — | 2,967 |
| Deferred income taxes | 2,261 | 61,771 |
| Unrealized foreign exchange gains | (4,046) | (5,306) |
| Other | (5,534) | (4,633) |
Item 1. Financial Statements
FAQ
- What is BioMarin Pharmaceuticals's stock-based comp?
- BioMarin Pharmaceuticals (BMRN) reported stock-based comp of $75.69M in Q2 2026.
- How has BioMarin Pharmaceuticals's stock-based comp changed year-over-year?
- BioMarin Pharmaceuticals's stock-based comp increased by 59.3% year-over-year, from $47.53M to $75.69M.
- What is the long-term trend for BioMarin Pharmaceuticals's stock-based comp?
- Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's stock-based comp has grown at a -2.1% compound annual growth rate (CAGR), from $197.26M to $181.41M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about BioMarin Pharmaceuticals's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude